A mast cell (also known as a mastocyte or a labrocyte) is a resident cell that develops and lives in connective or mucosal tissue and contains many small secretory granules for the storage and release of histamine, heparin and other mediators. Derived from myeloid progenitor cells, mast cells are granulocytes, a type of white blood cell, and part of the immune and neuroimmune systems. Mast cells were described by Friedrich von Recklinghausen in 1863 and rediscovered and named by Paul Ehrlich in 1877.
Mast cells act as sentinels, detecting signals that indicate the presence of parasites, pathogens and other possible dangers in surrounding cells and tissues. MCs modulate immune responses according to the stimuli detected, both by releasing mediators stored in granules and by secreting newly synthesized mediators. They play an important protective role in the defense and repair of cells through wound healing, angiogenesis, vascular permeability, and responses to bacteria, viruses, protozoa, prions, fungi, and venoms. MCs are best known for their roles in allergy, anaphylaxis, and atopic dermatitis and may be involved in a variety of other diseases.
Development Mast cells are considered to have originated nearly 500 million years ago, in urochordates, making them one of the most ancient types of immune cells. Mast cells (MCs) are specialized immune cells derived through hematopoiesis, the formation of blood cell components. Mast cells develop from circulating mast cell progenitors (MCps). Once they are recruited to a given type of connective or mucosal tissue, they specialize and become resident mast cells. Mature MCs exhibit context-specific effector properties related to tissue types and diseases, and are highly varied. Mast cells in different tissues, such as gut and skin, will exhibit different physical, behavioral, and biochemical characteristics and functions.
Mast cells may have dual methods of origin in the hematopoietic system. In 1989, Leonore Herzenberg and Leonard Herzenberg proposed that different types of stem cells produce specific types of immune cells through multiple waves of development. Specific types of immune cells have been shown to arise sequentially at different points in embryonic development. The original layered immune theory proposed that hematopoietic stem cells (HSCs) were the basis for such development. In the classical sequence of hematopoiesis, hematopoietic stem cells (HSCs) were described as becoming multipotent progenitors (MPPs), then differentiating into common myeloid progenitors (CMPs), followed by granulocyte/monocyte progenitors (GMPs). GMPs then differentiated into mast cells and basophils.
However, lineage relationships in human hematopoiesis have been hotly debated. Subsequent research suggests that multiple waves of immune cells develop through hematopoiesis from hemogenic endothelial cells (ECs), independent of HSCs, with HSCs arising in a later hematopoietic wave. Tissue-resident immune cells may be either fetal-derived or the progeny of adult HSCs.
In vertebrates, the earliest source of mast cells is the extraembryonic yolk sac, where blood and immune cells first develop. However, there are differences in the embryonic development of vertebrates such as mice compared to primates (including humans). In primates, yolk sac formation involves a transient primary yolk sac, and the formation of extraembryonic mesoderm, prior to generation of a secondary yolk sac where the first blood cells of the embryo develop.
During embryonic development, mast cell progenitors (MCps) form in a series of developmentally discrete waves. The first wave of mast cells in the embryo is derived from erythro-myeloid progenitors (EMPs) in the yolk sac, before hematopoietic stem cells (HSC) emerge. In mouse models, the earliest mast cell progenitors originate in the embryo around embryonic day 7 (E7.5-E8.5). Transient erythro-myeloid progenitors (EMPs) develop in the yolk sac between E8.5-E10.5 and in fetal liver (FL) between E11.5-E13.5. Embryonic multipotent progenitors (eMPPs) and hematopoietic stem cells (HSCs) emerge around E10.5. Mast cell differentiation in the fetal liver (FL) starts from E11, along with a peak in the number of mast cell progenitors. Mast cell progenitors then enter the circulation and seed other tissues including the brain, heart, lung, peritoneal cavity, skin, and spleen, where they complete their maturation. eMPPs and HSCs start producing mature hematopoietic cells in the fetal liver around E12.5 and E14.5 respectively. HSCs are able to produce mast cells within a limited time window, declining after embryonic day E14.5.
Whether mast cells originate mostly independent of HSCs, or "adult" mast cells originate in bone marrow (BM) from HSCs is debated. MC precursors of myeloid origin are found in bone marrow, but mature MCs are absent. Mast cells are easily generated from adult BM cells in vitro, but this has been less successful following HSC transplantation in vivo. It is unclear whether fetal-derived immune cells may be produced by HSCs during the fetal to neonatal period.
In humans, the first yolk sac-derived MCs originate from mesodermal precursors that form in blood islands of the yolk sac, starting around three weeks into gestation. From there, circulating progenitors migrate into peripheral tissues for complete differentiation and maturation. Hematopoietic progenitors subsequently differentiate into multiple lineages, including erythroid, lymphoid, megakaryocytic, and myeloid precursors, which emerge in the fetal liver. Immature MCs are activated by antigens and cytokines and become specialized in response to their resident environment. MCs become widely distributed throughout all tissues including the brain. Sizeable populations of fetal-derived MCs persist in connective tissue into adulthood, and appear to self-maintain mostly independent of bone marrow.
Structure
Mast cells are highly versatile immune cells that first appear during fetal development. Individual mast cells likely reflect the processes by which they originally develop as well as the microenvironments where they mature.
Mast cell progenitors, sometimes referred to as "immature" mast cells, circulate in the bloodstream as undifferentiated mononuclear cells. Circulating progenitors are similar in size to lymphocytes, and have fewer granules than mature mast cells. Circulating MC progenitors in human blood and in human bone marrow have been identified using the expression of the c-Kit (CD117) marker and the CD34 marker. CD34 is a widely expressed cell surface antigen found in cells with both progenitor-like and mature properties, making it difficult to distinquish between origins.
Once mast cell progenitors reach a destination tissue, they mature into resident granulated mast cells. Mature mast cells are also mononuclear. Healthy mature mast cells present a distinct immunophenotype in which expression of CD117 is high; CD33, CD9 and CD71 are intermediate; CD11b and CD38 are low; and HLA-DR, CD34, and CD123 are absent. Mast cells are present in most tissues and characteristically surround blood vessels, nerves and lymphatic vessels. They are especially prominent near the boundaries between the outside world and the internal milieu, such as the skin, mucosa of the lungs, and digestive tract, as well as the mouth, conjunctiva, and nose.
Mature resident mast cells are categorized based on their tissue location, granule protease content, and functional characteristics. In rodents, the two major categories of mature mast cells are connective tissue-resident mast cells (CTMCs) and mucosal mast cells (MMCs). Connective tissue mast cells contain heparin and large amounts of histamine and carboxypeptidase in their granules, and are distributed in the skin, peritoneal cavity, intestinal submucosa, and perivascular space around blood vessels. Mucosal mast cells predominantly contain chondroitin sulfate with small amounts of histamine and carboxypeptidase and are distributed in the mucosa of the lung and gastrointestinal tract. CTMCs express high levels of mouse mast cell protease (mMCP)-4,-5 (chymases) and -6,-7 (tryptases), but not mMCP-1 and-2 (chymases), whereas MMCs express mMCP-1 and -2 and not mMCP-4,-5 and -6.
In humans, three main categories of MCs have been identified based on the proteases they express. MCT expresses tryptase and resides primarily in mucosa of the lung and small intestine. MCTC expresses tryptase, chymase, and carboxypeptidase and resides primarily in the skin, lymph nodes, and lung and gut submucosa. ~98% of all mast cells in the mucosa of the human small intestine are MCT, while only ~13% of MCs in submucosa are MCT. A third form, MCC, expresses chymase but not tryptase. MCT somewhat resembles rodent MMC, while MCTC somewhat resembles rodent CTMC. Mast cells are still heterogenous within these main categories. In humans, at least six possible subsets of MCs with consistently expressed genes (or transcripts) have been observed across twelve organs. Some of these appear to be preferentially distributed (MC1, skin and lungs; MC2, MC3, MC4, skin and bladder; MC5, lymph node and vasculature; MC6, trachea and lungs).
Function
Mast cells are seen as "first responders" that deal with pathogens by alerting other immune cells and coordinating immune responses in the innate and acquired immune systems. When activated, a mast cell can either selectively release (piecemeal degranulation) or rapidly release (anaphylactic degranulation) compounds or mediators from storage granules into the local environment. In addition to the rapid release of pre-formed stored mediators, mast cells can also secrete newly synthesized mediators.
The activation of mast cell receptors in specific signaling networks leads to the selective release of mediators that manage both local rapid reactions and long-term responses to stimuli. As part of a healthy immune system, mast cell mediators manage cycles of inflammation and repair, initially producing inflammation to counter harmful stimuli and later repairing damaged tissues to restore homeostasis. MCs play an important protective role in the defense and repair of cells through wound healing, angiogenesis, vascular permeability, and responses to bacteria, parasites, fungi, viruses and venoms. Dysfunction of mast cells is linked to a variety of diseases: MCs are best known for their roles in allergy, anaphylaxis, and eczema (atopic dermatitis).
Mast cells play a key role in the inflammatory process. Histamine dilates post-capillary venules, activates the endothelium, and increases blood vessel permeability. This leads to local edema (swelling), warmth, redness, and the attraction of other inflammatory cells to the site of release. It also depolarizes nerve endings (leading to itching or pain). Cutaneous signs of histamine release are the "flare and wheal" reaction. The bump and redness immediately following a mosquito bite are a good example of this reaction, which occurs seconds after challenge of the mast cell by an allergen.
Signaling pathways for mast cell activation Specific signaling pathways of mast cells in different tissues provide mechanisms by which the immune system detects and is organized to deal with potential threats. Mast cells can be stimulated to degranulate by allergens through cross-linking with immunoglobulin E receptors (e.g., FcεRI), physical injury through pattern recognition receptors for damage-associated molecular patterns (DAMPs), microbial pathogens through pattern recognition receptors for pathogen-associated molecular patterns (PAMPs), and various compounds through their associated G-protein coupled receptors (e.g., morphine through opioid receptors) or ligand-gated ion channels. Complement proteins can activate membrane receptors on mast cells to exert various functions as well.